Synaptogenix Inc. logo

SNPX

NASDAQ

Synaptogenix Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
$24.74+0.44 (+1.83%)
Website
News25/Ratings0

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

Latest news

25 items